Monday, November 21, 2016

PLGA from PolySciTech used in development of vaccine nanoparticle for improved efficacy

In the field of vaccines, occasionally the application of the antigen alone is not enough to induce a full immune response. In this case, an adjuvant or delivery system is utilized in order to improve the immune response. Recently, researchers utilized PolySciTech (www.PolySciTech.com) PLGA (75:25) (PolyVivo cat# AP054) for developing a nanoparticle for enhancing vaccine performance. This research holds promise for improved development of vaccines that result in a strong immune response to prevent future infections. Read more: Guldner, Delphine, Julianne K. Hwang, Maria Clara D. Cardieri, Meaghan Eren, Parissa Ziaei, M. Grant Norton, and Cleverson D. Souza. "In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A." PloS one 11, no. 11 (2016): e0165477 http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0165477

“Abstract: Poly (lactic-co-glycolic acid) nanoparticles (PLGA NPs) have been considerably studied as a promising biodegradable delivery system to induce effective immune responses and to improve stability, safety, and cost effectiveness of vaccines. The study aimed at evaluating early inflammatory effects and cellular safety of PLGA NPs, co-encapsulating ovalbumin (PLGA/OVA NPs), as a model antigen and the adjuvant monophosphoryl lipid A (PLGA/MPLA NPs) as an adjuvant, on primary canine macrophages. The PLGA NPs constructs were prepared following the emulsion-solvent evaporation technique and further physic-chemically characterized. Peripheral blood mononuclear cells were isolated from canine whole blood by magnetic sorting and further cultured to generate macrophages. The uptake of PLGA NP constructs by macrophages was demonstrated by flow cytometry, transmission electron microscopy and confocal microscopy. Macrophage viability and morphology were evaluated by trypan blue exclusion and light microscopy. Macrophages were immunophenotyped for the expression of MHC-I and MHC-II and gene expression of Interleukin-10 (IL-10), Interleukin-12 (IL-12p40), and tumor necrosis factor alpha (TNF-α) were measured. The results showed that incubation of PLGA NP constructs with macrophages revealed effective early uptake of the PLGA NPs without altering the viability of macrophages. PLGA/OVA/MPLA NPs strongly induced TNF-α and IL-12p40 expression by macrophages as well as increase relative expression of MHC-I but not MHC-II molecules. Taken together, these results indicated that PLGA NPs with addition of MPLA represent a good model, when used as antigen carrier, for further, in vivo, work aiming to evaluate their potential to induce strong, specific, immune responses in dogs.”
Post a Comment